Improvement in clinical signs and cellular immunity of dogs with visceral leishmaniasis using the immunomodulator P-MAPA

Acta Tropica

Volumn 127, Issue 3, 2013, Pages 174-180

  Santiago, Maria Emília B ^a   Neto, Luiz Silveira ^a   Alexandre, Eduardo Costa ^a   Munari, Danísio Prado ^a   Andrade, Mariana Macedo C ^a   Somenzari, Marcos Arruda ^a   Ciarlini, Paulo César ^a   De Lima, V M F ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

CD4+ T; CD8+ T; Leishmania; P MAPA; T lymphocytes

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTILEISHMANIAL AGENT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; LEISHMANIA ANTIBODY; PHYTOHEMAGGLUTININ; PLACEBO; PROTEIN AGGREGATE MAGNESIUM AMMONIUM PHOSPHOLINOLEATE PALMITOLEATE ANHYDRIDE; PROTOZOAL ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY; ANTIGEN; BLOOD; CANID; DRUG; IMMUNITY; LEISHMANIASIS; PARASITE; SYMPTOM;

ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOG DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; IN VITRO STUDY; MONONUCLEAR CELL; NONHUMAN; PARASITE LOAD; PROMASTIGOTE; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; SKIN BIOPSY; SYMPTOMATOLOGY; T LYMPHOCYTE SUBPOPULATION; VISCERAL LEISHMANIASIS;

CD4(+) T; CD8(+) T; LEISHMANIA; P-MAPA; T LYMPHOCYTES;

ANIMALS; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; FEMALE; FUNGAL PROTEINS; GENE EXPRESSION REGULATION; IMMUNOLOGIC FACTORS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-2; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MALE;

CANIS FAMILIARIS;

EID: 84878395018     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2013.04.005     Document Type: Article

References (45)

1. Alvar J., Molina R., San Andrés M., Tesouro M., Nieto J., Vitutia M., González F., San Andrés M.D., Boggio J., Rodriguez F., Sainz A., Escacena C. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann. Trop. Med. Parasitol. 1994, 88:371-378.
2. Amorim I.F., Silva S.M., Figueiredo M.M., Moura E.P., Castro R.S., Lima T.K., Gontijo N., de F., Michalick M.S., Gollob K.J., Tafuri W.L. Toll receptors type-2 and CR3 expression of canine monocytes and its correlation with immunohistochemistry and xenodiagnosis in visceral leishmaniasis. PLoS ONE 2011, 6(11):e27679.
3. Baneth G., Shaw S.E. Chemotherapy of canine leishmaniosis. Vet. Parasitol. 2002, 106:315-324.
4. Bogdan C., Röllinghoff M., Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr. Opin. Immunol. 2000, 12:64-76.
5. Boggiatto P.M., Ramer-Tait A.E., Metz K., Kramer E.E., Gibson-Corley K., Mullin K., Hostetter J.M., Gallup J.M., Jones D.E., Petersen C.A. Immunologic indicators of clinical progression during canine Leishmania infantum infection. Clin. Vaccine Immunol. 2009, 17:267-273.
6. Borja-Cabrera G.P., Mendes A.C., Souza E.P., Okada L.Y.H., Trivellato F.A.A., Kawasaki J.K.A., Costa C.A., Reis A.B., Genaro O., Batista L.M.M., Palatnik M., Palatnik-De-Sousa C.B. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004, 22:2234-2243.
7. Bourdoiseau G., Bonnefont C., Magnol J.P., Saint Andre I., Chabanne L. Lymphocyte subset abnormalities in canine leishmaniasis. Vet. Immunol. Immunop. 1997, 56:345-351.
8. Brasil, 2011. Homepage of Ministério da Saúde, (accessed on 2.5.11). http://portal.saude.gov.br/portal/saude/visualizartexto.cfm?dtxt=27082.
9. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microb. 2004, 27:305-318.
10. Dos-Santos W.L., Jesus E.E., Paranhos-Silva M., Pereira A.M., Santos J.C., Baleeiro C.O., Nascimento E.G., Moreira E.D., Oliveira G.G., Pontes-De-Carvalho L.C. Associations among immunological, parasitological and clinical parameters in canine visceral leishmaniasis emaciation, spleen parasitism, specific test reaction. Vet. Immunol. Immunop. 2008, 123:251-259.
11. Durán N., Gowen B.B., Costa F.T.M., Justo G.Z., Brocchi M., Nunes O.S., Nunes I.S. A biotechnological product and its potential as a new immunomodulator for treatment of animal phlebovirus infection Punta Toro virus. Antivir. Res. 2009, 83:143-147.
12. Fávaro W.J., Nunes O.S., Seiva F.R.F., Nunes I.S., Woolhiser L.K., Durán N., Lenaerts A.J. Effects of P-MAPA immunomodulator on toll-like receptors and p53: potential therapeutic strategies for infectious diseases and cancer. Infect. Agent Cancer 2012, 7:14.
13. Ferrer L.M. Clinical aspects of canine leishmaniasis 1999, 6-10. Proc. International Canine Leishmaniasis Forum, Barcelona, Spain.
14. Fernández-Pérez F.J., Gómez-Muñoz M.T., Méndez S., Alunda J.M. Leishmania-specific lymphoproliferative responses and IgG1/IgG2 immunodetection patterns by Western blot in asymptomatic, symptomatic and treated dogs. Acta Trop. 2003, 86:83-91.
15. Ghose A.C., Mookerjee A., Sengupta K., Ghosh A.K., Dasgupta S., Ray P.K. Therapeutic and prophylactic uses of Protein A in the control of Leishmania donovani infection in experimental animals. Immunol. Lett. 1999, 65:175-181.
16. Guarga J.L., Moreno J., Lucientes J., Gracia M.J., Perinbánez M.A., Castillo J.A. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 2002, 88:13-20.
17. Guerra L.L., Teixeira-Carvalho A., Giunchetti R.C., Martins-Filho O.A., Reis A.B., Corrêa-Oliveira R. Evaluation of the influence of tissue parasite density on hematological and phenotypic cellular parameters of circulating leukocytes and splenocytes during ongoing canine visceral leishmaniasis. Parasitol. Res. 2009, 104:611-622.
18. Holzmuller P., Cavaleyra M., Moreaux J., Kovacic R., Vincendeau P., Papierok G., Lemerse J.L. Lymphocytes of dogs immunized with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis. Vet. Immunol. Immunopathol. 2005, 106:247-257.
19. Ikeda-Garcia F.A., Lopes R.S., Marques F.J., Ciarlini P.C., Lima V.M.F., de Morinishi C.K., Zanette M.F., Perri S.H.V., Marcondes M. Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate and allopurinol. Braz. J. Vet. Res. Anim. Sci. 2010, 47:218-223.
20. Jain N.C. Essentials of Veterinary Hematology 1993, 320. Lea & Febiger, Philadelphia.
21. Justo G.Z., Durán N., Queiroz M.L.S. Myelopoietic response in tumour-bearing mice by an aggregated polymer isolated from Aspergillus oryzae. Eur. J. of Pharmacol 2000, 388:219-226.
22. Justo G.Z., Durán N., Queiroz M.L. Natural killer cell activity, lymphocyte proliferation, and cytokine profile in tumor-bearing mice treated with MAPA, a magnesium aggregated polymer from Aspergillus oryzae. Immunopharmacol. Immunotoxicol. 2003, 25:305-319.
23. Lima V.M.F., Gonçalves M.E., Ikeda F.A., Luvizotto M.C.R., Feitosa M.M. Anti-leishmania antibodies in cerebrospinal fluid from dogs with visceral leishmaniasis. Braz. J. Med. Biol. Res. 2003, 36:485-489.
24. ® in an endemic area for visceral leishmaniasis. Vet. Immunol. Immunopathol. 2010, 135:296-302.
25. Lima V.M., Fattori K.R., de Souza F., Eugênio F.R., Santos P.S., Rozza D.B., Machado G.F. Apoptosis in T lymphocytes from spleen tissue and peripheral blood of L (L.) chagasi naturally infected dogs. Vet. Parasitol 2012, 184:147-153.
26. Maia C., Nunes M., Cristóvão J., Campino L. Experimental canine leishmaniasis: clinical. parasitological and serological follow-up. Acta Trop. 2010, 116:193-199.
27. Manna L., Reale S., Picillo E., Vitale F., Gravino A.E. Interferon-gamma (INF-(), IL4 expression levels and Leishmania DNA load as prognostic markers for monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinol. Cytokine 2008, 44:288-292.
28. +T cells turns on contra-T regulatory cell functions. J. Immunol. 2010, 184:5510-5518.
29. Marcondes M., Ikeda F.A., Vieira R.F., Day M.J., Lima V.M., Rossi C.N., Perri S.H., Biondo A.W. Temporal IgG subclasses response in dogs following vaccination against Leishmania with Leishmune®. Vet. Parasitol. 2011, 2011(181):153-159.
30. Melo A., Justo G.Z., Queiroz M.L.S. Stimulation of myelopoiesis in Listeria monocytogenes-infected mice by an aggregated polymer isolated from Aspergillus oryzae. Hum. Exp. Toxicol 2001, 20:38-45.
31. Michelin A.F., Perri S.H., De Lima V.M. Evaluation of TNF-α IL-4, and IL-10 and parasite density in spleen and liver of L. (L.) chagasi naturally infected dogs. Ann. Trop. Med. Parasitol. 2011, 105:373-383.
32. Miller R., Wen X., Dunford B., Wiang X., Suzuki Y. Cytokine Production of CD8 Immune T Cells but Not of CD4T Cells from Toxoplasma gondii-Infected Mice Is Polarized to a Type 1 Response Following Stimulation with Tachyzoite-Infected Macrophages. J. Interferon Cytokine Res. 2006, 26:782-792.
33. Moreno J., Nieto J., Chamizo C., González F., Blanco F., Barker D.C., Alvar J. The immune response and PBMC subsets in canine visceral leishmaniasis before and after, chemotherapy. Vet. Immunol. Immunopathol. 1999, 71:181-195.
34. Mosmann T. Rapid colorimetric assay for cellular growth and survivals: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
35. Nunes, I.S., Justo, G.Z., Durán, N., 2004. Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride immunomodulator, its production process and formulation. USA/PAT 10/978683.
36. Pinelli E., Gonzalo R.M., Boog C.J., Rutten V.P., Gebhard D., del Real G., Ruitenberg E.J. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner. Eur. J. Immunol 1995, 25:1594-1600.
37. Quaresma P.F., Murta S.M., Ferreira E.C., da Rocha-Lima A.C., Xavier A.A., Gontijo C.M. Molecular diagnosis of canine visceral leishmaniasis: identification of Leishmania species by PCR-RFLP and quantification of parasite DNA by real-time PCR. Acta Trop. 2009, 111:289-294.
38. Reis A.B., Giunchetti R.C., Carrillo E., Martins-Filho O.A., Moreno J. Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Trends Parasitol. 2010, 26:341-349.
39. Reis A.B., Teixeira-Carvalho A., Giunchetti R.C., Guerra L.L., Carvalho M.G., Mayrink W., Genaro O., Correa-Oliveira R., Martins-Filho O.A. Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin. Exp. Immunol. 2006, 146:303-311.
40. Rodgers M.R., Popper S.J., Wirth D.F. Amplification of kinetoplast as tool in the detection and diagnosis of Leishmania. Exp. Parasitol. 1990, 71:267-275.
41. Shakya N., Sane S.A., Vishwakarma P., Bajpai P., Gupta S. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv. Acta Trop. 2011, 119:188-193.
42. Smith A.C., Yardley V., Rhodes J., Croft S.L. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 2000, 44:1494-1498.
43. Solano-Gallego L., Koutinas A., Miró G., Cardoso L., Pennisi M.G., Ferrer L., Bourdeau P., Oliva G., Baneth G. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet. Parasitol. 2009, 165:1-18.
44. World Health Organization - Technical Report Series, 2010. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva, March 22-26.
45. Zafra R., Jaber J.R., Pérez-Ecija R.A., Barragán A., Martínez-Moreno A., Pérez J. High iNOS expression in macrophages in canine leishmaniasis is associated with low intracellular parasite burden. Vet. Immunol. Immunopathol. 2008, 123:353-359.